HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $400.
June 24, 2024 | 5:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Alnylam Pharmaceuticals and maintained a price target of $400.
The reiteration of a Buy rating and a high price target of $400 by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive short-term price appreciation for Alnylam Pharmaceuticals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100